A Phase 1, Single Center, Randomized, 4-way Crossover, Double Blinded, Placebo And Moxifloxacin Controlled Study To Evaluate The Effect Of Glasdegib On The Cardiac Repolarization In Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 05 Oct 2017
At a glance
- Drugs Glasdegib (Primary) ; Moxifloxacin
- Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Haematological malignancies; Myelodysplastic syndromes; Myelofibrosis; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 05 Jul 2017 Planned End Date changed from 23 Oct 2017 to 16 Oct 2017.
- 05 Jul 2017 Planned primary completion date changed from 25 Sep 2017 to 23 Sep 2017.
- 05 Jul 2017 Status changed from not yet recruiting to recruiting.